Age and biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
Patients aged 16-24 years with psoriasis are more likely to stop TNFi due to ineffectiveness, whereas those aged ≥ 55 years are more likely to stop biologics due to AEs. These real-world findings provide important information for clinicians treating people with moderate-to-severe psoriasis across all age groups.
Authors
- Shehnaz Ahmed (ORCID: https://orcid.org/0000-0003-0744-4985)
- Tess McPherson (ORCID: https://orcid.org/0000-0001-9215-0302)
- Alexa R. Shipman (ORCID: https://orcid.org/0000-0001-5257-4418)
- Philip Hampton (ORCID: https://orcid.org/0000-0001-6797-2697)
- Ian Evans (ORCID: https://orcid.org/0000-0002-0468-8274)
- Simon Morrison
- Zenas Z N Yiu (ORCID: https://orcid.org/0000-0002-1831-074X)
- Girish Kumar Gupta (ORCID: https://orcid.org/0000-0002-6981-4024)
- Olivia Hughes (ORCID: https://orcid.org/0000-0001-9587-9430)
- Philip Laws (ORCID: https://orcid.org/0000-0002-4628-0699)
- Oras Alabas (ORCID: https://orcid.org/0000-0003-2002-0781)
- Nick J. Reynolds (ORCID: https://orcid.org/0000-0002-6484-825X)
- Christina Ye
- Teena Mackenzie
- Elise Kleyn
- Anthony D. Ormerod (ORCID: https://orcid.org/0000-0003-4075-6374)
- Shernaz Walton (ORCID: https://orcid.org/0009-0009-1018-1320)
- Ruth Murphy (ORCID: https://orcid.org/0000-0003-2159-5958)
- Juliet N. Barker (ORCID: https://orcid.org/0000-0002-9030-183X)
- Anthony Bewley (ORCID: https://orcid.org/0000-0003-1195-0290)
- Brian Kirby (ORCID: https://orcid.org/0000-0001-7596-892X)
- K.J. Mason (ORCID: https://orcid.org/0000-0002-5419-0669)
- Christopher E.M. Griffiths (ORCID: https://orcid.org/0000-0001-5371-4427)
- Vera Zietemann (ORCID: https://orcid.org/0000-0002-3382-5506)
- Richard Bruce Warren (ORCID: https://orcid.org/0000-0002-2918-6481)
- Catherine Smith (ORCID: https://orcid.org/0000-0001-9918-1144)
- Richard Weller (ORCID: https://orcid.org/0000-0003-2550-9586)
- Christopher Griffiths
- Kathleen McElhone
Institutions
- Novartis (Switzerland) (CH)
- Bristol-Myers Squibb (Germany) (DE)
- Eli Lilly (United States) (US)
- King's College London (GB)
- Pfizer (United Kingdom) (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Leo Pharma (Australia) (AU)
- Manchester Academic Health Science Centre (GB)
- University of Manchester (GB)
- Northern Health and Social Care Trust (GB)
- Janssen (France) (FR)
- Manchester University NHS Foundation Trust (GB)
- Samsung (United States) (US)
- Arthritis UK (GB)
- Galderma (France) (FR)
- Boehringer Ingelheim (India) (IN)
- Almirall (Spain) (ES)
- King's College Hospital (GB)
- NIHR Manchester Biomedical Research Centre (GB)
- Keele University (GB)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1093/bjd/ljaf017
- Citations
- 3
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 2.39
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- Sanofi
- Celgene
- National Institute for Health and Care Research
- British Association of Dermatologists
- Swedish Orphan Biovitrum
- Manchester Biomedical Research Centre
- Medical Research Council
- UCB Pharma
- Cilag